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Introduction
In 2008, pharmacy organizations established the five core elements of a medication therapy
management (MTM) service model: medication therapy review, a personal medication record,
medication action plan, intervention and/or referral, and documentation and follow-up.1 These
services solve problems related to polypharmacy, preventable adverse drug events, medication
adherence, and medication misuse.2 A plethora of literature exists demonstrating the positive
patient outcomes from pharmacist-lead MTM services. A 2010, meta-analysis analyzed 298
randomized controlled trials where patients received direct patient care from pharmacists. The
analysis demonstrated improvements in patient's HbA1c in patients with diabetes, blood pressure
in patients with hypertension, medication adherence, quality of life, and patient satisfaction. The
study also saw a reduction in the number of patients' sick days taken and hospitalization. Upon
economic analysis, the range of return on investments for these services ranges from 2:1 to 12:1
in favor of MTM services provided by pharmacists.3
Though there is an abundance of data concerning the benefits of pharmacists-lead MTM services
in the United States, few look at if these benefits are seen equally between English and non-English
speaking patients. There is also little data that analyzes if there is a difference in the volume or
categorization of drug therapy problems (DTPs) faced by patients with these language barriers.4
The United States’ government defines a limited English proficient (LEP) individual as a person
who does not “speak English as their primary language and… [has] a limited ability to read, speak,
write or understand English.”5 Limited English proficiency is also defined as the ability to speak
English less than "very well"; nearly one in eleven individuals meet this criterion in the United
States.6 Under executive order 13166, LEP individuals should have “meaningful access” to
language services at federally conducted and federally funded programs and activities.5 Though
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laws requiring access to language services in the healthcare system have been passed, 7 LEP
patients still feel the effects of their language barriers.
An Institute of Medicine report indicated that poor comprehension of prescription medication
instructions was the cause of many adverse drug events and medication errors.8 Previous studies
conducted in the LEP population have discovered that this higher rate of prescription instruction
misunderstandings can lead to a higher rate of adverse drug events, unsafe medication use, and
poor drug adherence.4,9-13 Even when language services are provided, health disparities still exist.
One study found children of families with LEP were less likely to have their pain assessed or
receive opioids postoperatively than children of English proficient (EP) families with similar pain
scores.14
A previous study conducted in the Minneapolis-St. Paul area of Minnesota, published in 2005,
sought to determine whether the types of DTPs identified during pharmaceutical care assessments
differed between English speaking and non-English speaking patients. The primary languages
spoken by the 38 non-English speaking patients included: Vietnamese, Hmong, Laotian, Somali,
Spanish, and Khmer. During the pharmacist visits for the 91 study participants, a total of 186 DTPs
were identified. A higher percentage of patients within the non-English speaking arm had DTPs
categorized as non-adherence compared to the English speaking arm (31% vs. 12%).4 A separate
survey of pharmacists and physicians at a Canadian ambulatory care center sought to study how
pharmaceutical care was provided to LEP patients. Pharmacists and physicians also noted a higher
rate of DTPs related to non-adherence in the LEP patients.15
The objective of this study is to determine if there is a difference between the volume and
categorization of drug therapy problems, and subsequent medication adherence or chronic disease
management outcomes in patients with limited English proficiency.
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Methods
Study Oversight and Funding
This study is a subset of a grant project funded from the Connecticut Department of Public Health,
as the pharmacy initiative component of the comprehensive chronic disease grant from the Centers
for Disease Control and Prevention (CDC). The original CDC grant was entitled "State Public
Health Actions to Prevent and Control Diabetes, Heart Disease, Obesity and Associated Risk
Factors and Promote School Health." The study protocol and subsequent revisions were reviewed
by the University of Connecticut's Institutional Review Board.
Study Design
Community pharmacists that service underserved populations were certified to provide MTM
services. The overall study targeted a population of patients with hypertension and/or diabetes to
receive these services.
Patient recruitment occurred in one of four ways. First, patients with prescriptions for hypertension
and/or diabetes medications were contacted at point-of-service at the pharmacy. When the patient
picked up their prescription(s), the dispensing pharmacist would alert the patient that they may be
a candidate for the study. At the same time, a flier describing the MTM study would be attached
to their prescription bag. Fliers detailing the study were also posted at senior housing complexes
surrounding the pharmacies participating in the study. Fliers detailing the study were also given to
local physicians who have patients that utilize the community pharmacies where the study took
place. Lastly, study investigators also planned to use word of mouth to help recruit family and
friends of current study participants.
Over the course of a twelve-month period, patients completed up to four MTM visits. During these
visits pharmacists collected a full medication list, performed a comprehensive medication review,
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educated patients on self-management techniques, developed a mutually agreed upon action plan,
and conducted an assessment of the appropriateness of, the effectiveness of, the safety of, and
adherence to therapy.
For this author’s analysis, patients were separated into arms based on the language their visits were
conducted in. Patients were put into the English Proficiency (EP) arm if their visits were conducted
in English and informed consent forms were provided in English. Patients were put into the limited
English proficiency (LEP) arm if their visits were conducted in Spanish or their informed consent
form was provided in Spanish. Only data from the study participants at Arrow Pharmacy at 500
Farmington Avenue in Hartford, CT was included. The site had three pharmacists that were trained
in human subjects research and certified to perform MTM services through the UConn Office of
Pharmacy Professional Development. Additionally, three bilingual pharmacy technicians were
involved in patient visits to provide Spanish translation services.
Study Population
Patients were eligible for inclusion into the original study if they were 18 years or older and had
at least one prescription medication for diabetes and/or hypertension. Additionally, patients had to
speak either English or Spanish and sign an informed consent form in either the English or Spanish
translation. Patients were excluded from the study if they had a diagnosis of Alzheimer’s disease
or were receiving any of the following drugs: donepezil, galantamine, memantine, or rivastigmine.
An additional inclusion criterion for this author's analysis required that patients complete their
visits at Arrow Pharmacy at 500 Farmington Avenue in Hartford, CT.
Endpoints
The primary endpoint of this study was the number of DTPs identified per patient. Secondary
outcomes for the study included: change in systolic blood pressure, change in diastolic blood

6

pressure, change in HbA1c, and change in adherence behavior as measured by the Modified
Morisky Adherence Scale (MMAS). Additionally, the number of patients at their blood pressure
and HbA1c goals at baseline and final visit were analyzed. The net change of the number of
patients at goal in both arms was also compared. For all patients, a blood pressure goal was set at
140/90 mmHg. For patients with diabetes, an HbA1c goal of 9% was utilized.
The MMAS is a self-administered tool that provides patients with a score ranging from 0 to 8. A
value less than 6 indicates low adherence. A value of 6 or 7 indicates medium adherence. A value
of 8 indicates high adherence.16 The number of patients within each adherence category were also
compared between each arm. The net number of patients within each arm that improved their
adherence categorization (i.e. low adherence to medium adherence) were analyzed.
To calculate these values, data related the patient’s baseline and final systolic and diastolic blood
pressure, HbA1c, and MMAS were collected. Additional secondary endpoints included analysis
of DTP categorization. DTPs identified by pharmacists could be categorized into one of seven
categories, including Unnecessary Drug Therapy, Needs Additional Drug Therapy, Needs
Different Drug Product, Dosage Too Low, Adverse Drug Reaction, Dosage Too High, and NonAdherence.
Data related to a patient’s sex, age, race or ethnicity, social history, comorbidities, and medications
were used to analyze patients’ baseline characteristics.
Statistical Analysis
During a patient’s first visit, baseline data including a patient’s sex, age, race or ethnicity, smoking
history, use of alcohol, comorbid conditions, MMAS score, and current medication list were
collected by pharmacists. The mean data for age, total number of comorbid conditions, total
number of medications, and number of medications per morbid conditions was compared.
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The baseline characteristics were compared using one of two statistical tests. Age, total number of
comorbidities, total number of medications, and medications per comorbid condition were
analyzed using a two-tailed unpaired T-test. Comparisons of population proportions for
characteristics including, sex, race, ethnicity, tobacco use, alcohol use, and individual
comorbidities were made using a two-tailed Z-Test of proportions.
Due to the study’s small size, a formal power calculation was not performed. The final analysis
would be an intention to treat analysis. A two-tailed unpaired T-test was utilized to compare
differences between the arms in terms of the primary endpoint of the number of DTPs identified
per patient. A two-tailed unpaired t-test was also utilized to compare differences between the arms
for the secondary endpoints of change in medication adherence score as calculated by the MMAS,
change in systolic blood pressure, change in diastolic blood pressure, and change in HbA1c. A
two-tailed Z-test of proportions was utilized to analyze the secondary outcomes of individual DTP
categorization, net adherence category improvement, and change in the number of patients at blood
pressure and HbA1c goals. A two-sided alpha of 0.05 would be considered significant. All analysis
was performed utilizing Microsoft Excel 2013.
Results
Study Participants
The data analyzed in the study was collected from a total of fifty-eight patients at Arrow Pharmacy
in Hartford, CT from May 9, 2014 to May 13, 2016. All fifty-eight patients completed at least two
MTM visits. A total of fifty-three patients, eleven patients (100%) within the LEP arm and fortytwo patients (89.3%) within the EP arm, completed their third MTM visit. A total of six patients,
one patient (9.1%) in the LEP arm and five patients (10.6%) within the EP arm, completed a fourth
visit. Overall, 175 patient visits were conducted during the study period.
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Of the fifty-eight patients, eleven had limited English proficiency (LEP) and were provided a
translator so the visits could be conducted in Spanish. The remaining forty-seven patients made up
the English proficiency (EP) arm of the study and had their visits conducted in English without
translation services.
As shown in the baseline characteristics table below (Table 1), the majority of patients in both
arms were female (63.7% in the LEP arm and 59.6% in the EP arm). The average age of patients
was 64.1 years. In the LEP arm, each of the 11 patients (100%) identified as Hispanic or Latino
and nine of the patients (81.8%) identified as white. In the EP arm, 32 patients (55.2%) identified
as Hispanic or Latino, 28 patients (48.3%) identified as white, 22 patients (37.9%) identified as
Black or African American, and one patient (1.7%) identified as Asian. The majority of patients
included in the study identified with more than one racial or ethnic group.
In both arms of the study, the majority of patients stated that they were never smokers (54.4% in
the LEP arm and 74.5% in the EP arm, p=0.190). A greater proportion of patients within the EP
arm (21.3%) stated that they were current smokers than those within the LEP arm (9.1%), p=0.352.
A greater proportion of patients in the LEP arm stated that they have a history of smoking tobacco,
but are not current users (36.4% vs. 4.3% in the EP arm, p=0.002). The majority of patients in both
arms of the study denied alcohol use. Thirteen patients (27.7%) in the EP arm and zero patients
(0%) in the LEP arm stated rare, social, or occasional alcohol use, p=0.048.
On average, patients with LEP stated a history of more medical comorbidities (5.2 conditions) than
those in the EP arm (3.5 conditions), p=0.009. The majority of patients in this study had
hypertension (100% vs. 95.7% respectively), type 2 diabetes mellitus (100% vs. 61.7%, p=0.014),
and hyperlipidemia (90.1% vs. 44.7%, p=0.006). Other common comorbidities included:
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Baseline Characteristics (Chart 1)
Patients with
Limited English
Proficiency
(n=11)

Patients with
English
Proficiency
(n=47)

Total
(n=58)

P-Value

4 (36.3%)
67.5 years

19 (40.4%)
63.2 years

23 (39.6%)
64.1 years

0.803
0.349

9 (81.8%)
11 (100%)
0 (0%)

19 (40.4%)
21 (44.7%)
22 (46.8%)

28 (48.3%)
32 (55.2%)
22 (37.9%)

0.014
> 0.001
0.004

0 (0%)

1 (2.1%)

1 (1.7%)

0.624

1 (9.1%)

10 (21.3%)

11 (19.0%)

0.352

4 (36.4%)

2 (4.3%)

6 (10.3%)

0.002

6 (54.5%)

35 (74.5%)

41 (70.7%)

0.190

0 (0%)

13 (27.7%)

13 (22.4%)

0.048

11 (100%)

34 (72.3%)

45 (77.6%)

0.048

11 (100%)
11 (100%)

45 (95.7%)
29 (61.7%)

56 (96.6%)
40 (70.0%)

0.484
0.014

10 (90.1%)
5 (45.5%)
2 (18.1%)
4 (36.4%)
5.2 conditions

21 (44.7%)
9 (19.1%)
9 (19.1%)
13 (27.7%)
3.5 conditions

31 (53.4%)
14 (24.1%)
11 (19.0%)
17 (29.3%)
3.8
conditions

0.006
0.066
0.944
0.569
0.009

9.4 medications

6.7 medications

0.024

1.8 medications per
conditions

1.9 medications per
conditions

7.2
medications
1.9
medications
per
conditions

Demographics
Male Sex
Age

Race/Ethnicity
White
Hispanic or Latino
Black or African
American
Asian

Social History
Smoking
Current
Smoker
History of
Smoking
Never-Smoker
Alcohol Use
States Alcohol
Use
Denies Use

Comorbidities
Hypertension
Type 2 Diabetes
Mellitus
Hyperlipidemia
Asthma
Ulcers
Depression
Total Number of
Comorbidities

Medications
Total Number of
Medications
Medications per
Comorbid
Conditions

0.823
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depression (36.4% vs 27.7%), asthma (45.5% vs 19.1%, p=0.066), and ulcer disease (18.1% vs
19.1%). Other comorbidities included: arthritis, COPD, gastroesophageal reflux disease, and
osteoporosis. Four patients stated they had a previous heart attack.
Patients within the LEP group also took a larger number of medications, 9.4 medications on
average, compared to patients with English proficiency at 6.7 medications, p=0.024. However, the
average number of medications per comorbid condition was similar between groups at 1.8
medications per comorbid condition in the LEP group and 1.9 medications per comorbid condition
in the EP group, p=0.823.
Primary Endpoint
Overall, a total of 115 drug therapy problems were identified for the fifty-eight patients involved
in the study. Twenty-two drug therapy problems were identified in patients within the LEP arm,
while ninety-three drug therapy problems were identified within patients in the EP arm. In terms
of the primary endpoint, the number of drug therapy problems identified per patient, a statistically
significant difference was not found. A mean of 2.00 DTPs were identified for each patient in the
LEP arm and 1.98 DTPs were identified for each patient in the EP arm with a p-value of 0.959.
As shown in the graph below (Figure 1), the overall mode was one drug therapy problem per
patient (18 patients). The mode for LEP patient was three drug therapy problems; for EP patients
it was one drug therapy problem. A total of four patients (8.5%) within the EP arm and one patient
(9.1%) within the LEP arm had zero DTPs identified. A total of fifteen patients (31.9%) with EP
and three patients (27.3%) with LEP had one DTP identified. Fourteen patients (29.8%) with EP
and 2 LEP patients (18.2%) had two DTPs identified. A total of eight patients (17.0%) in the EP
group and five patients (45.5%) in the LEP group had three DTPs identified. Six patients (12.8%)
in the EP group had greater than or equal to four DTPs identified.
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Number of Drug Therapy Problems per Patient (Figure 1)
20

Number of Patients

18
16
14
12
10
8
6
4
2
0
0

1

2

3

>4

Number of Drug Therapy Problems
EP

LEP

Secondary Endpoints
Drug Therapy Problem Categorization
Similarly to the primary endpoints, the secondary endpoints of DTP categorization did not reach
statistical significance. A similar proportion of patients within both arms had the DTPs categorized
as Needs Additional Drug Therapy (45.5% vs. 42.6%, p= 0.865) and Dosage Too Low (18.2% vs
17.0%, p=0.928). Though not statistically significant, the greatest proportional difference occurred
in the DTPs of Unnecessary Drug Therapy (18.2% vs. 6.4%, p=0.208), Needs Different Drug
Product (9.1% vs. 19.1%, p= 0.430), Adverse Drug Reaction (18.2% vs. 38.3%, p=0.207), and
Non-Adhearence (81.8% vs 70.2%, p=0.435). Lastly, a higher percentage of patients within the
LEP arm (9.1%) compared to the EP arm (4.3%) had the DTP of Dosage Too High documented,
p=0.516.
Of the 115 total drug therapy problems that were identified, 42 problems (36.5%) were categorized
as Non-Adherence. The second most common category was Needs Additional Drug Therapy, with
25 problems (21.7%) identified. The remaining categories of Adverse Drug Reaction, Dosage Too
12

DTP and Adhearence Outcomes (Chart 2)
Patients with
Limited English
Proficiency (n=11)

Patients with
P-Value
English
Proficiency (n=47)

Primary Outcome
Number of DTPs per
Patient

2.00

1.98

0.959

2 (18.2%)
5 (45.5%)

3 (6.4%)
20 (42.6%)

0.208
0.865

1 (9.1%)

9 (19.1%)

0.430

2 (18.2%)
2 (18.2%)
1 (9.1%)
9 (81.8%)

8 (17.0%)
18 (38.3%)
2 (4.3%)
33 (70.2%)

0.928
0.207
0.516
0.435

5

4.47

5.91

5.46

0.91

0.98

5 (45.5%)

29 (61.7%)

6 (54.5%)

22 (46.8%)

4 (36.4%)

12 (25.5%)

3 (27.3%)

20 (42.6%)

2 (18.2%)

6 (12.8%)

2 (18.2%)

5 (10.6%)

-1

6

Secondary Outcomes
DTP Categorization
Unnecessary Drug Therapy
Needs Additional Drug
Therapy
Needs Different Drug
Product
Dosage Too Low
Adverse Drug Reaction
Dosage Too High
Non-Adhearence

Medication Adherence
Baseline Morisky
Adherence Value
Morisky Adherence Value
at Final Visit
Change in Morisky
Adherence Value
Patients with Low
Adherence at Baseline
Patients with Low
Adherence at Final Visit
Patients with Medium
Adherence at Baseline
Patients with Medium
Adherence at Final Visit
Patients with High
Adherence at Baseline
Patients with High
Adherence at Final Visit
Net Adherence Category
Improvement

0.861

0.020
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Low, Needs Different Drug Product, Unnecessary Drug Therapy, and Dosage Too High had a
respective 20 (17.4%), 10 (8.7%), 10 (8.7%), 5 (4.3%), and 3 (2.6%) problems identified within
them.
Adherence Outcomes
Patients within the LEP arm had an average baseline adherence of 5.00 determined by the MMAS.
During their last visit, patients within the LEP arm had an average score of 5.91 on the MMAS,
giving them an average change of 0.91. In the EP arm, it was determined that patients had a
baseline adherence score of 4.47 with an average score of 5.46 on the MMAS at their final visits.
Patients within the EP arm saw a similar average change to the LEP group of 0.98, resulting in a
p-value of 0.861.
In the LEP arm, five patients (45.5%) had and MMAS value that placed them at low adherence at
baseline. At baseline, four patients (36.4%) had medium adherence and two patients (18.2%) had
high adherence in the LEP arm. In the EP arm, twenty-nine patients (61.7%) had low adherence,
twelve patients (25.5%) had medium adherence, and six patients had high adherence at baseline.
At the final visit, one of the patients in the LEP arm originally calculated to have medium
adherence now had low adherence. No other patients within the LEP arm changed adherence
category, giving the arm a net adherence category improvement of negative one patient. At the
final visit for patients within the EP arm, twenty-two patients (46.8%) were categorized as having
low adherence, twenty patients (42.6%) had medium adherence, and five patients (10.6%) had
higher adherence. Within the EP arm, seven patients characterized with low adherence at baseline
had medium adherence at their final visit; however, an additional patient that was characterized as
having high adherence at baseline was calculated to have medium adherence at their final visit.
This resulted in a net adherence category improvement of 6 patients for the EP group. The
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difference in net adherence category improvement was statistically significant with a p-value of
0.020.
Health Outcomes
When looking at the secondary outcomes of change in systolic blood pressure, diastolic blood
pressure, and HbA1c, no statistical significance was seen.
Patients within the LEP group had an average baseline systolic blood pressure of 141.55 mmHg
and a final systolic blood pressure of 139.55 mmHg. An average change of -2 mmHg in LEP
patient’s systolic blood pressure was seen. Patients within the EP arm had average baseline systolic
blood pressure of 143.23 mmHg and final systolic blood pressure of 138.62 mmHg. Overall, a
larger change in systolic blood pressure was seen in the EP group at -4.62 mmHg, p= 0.470.
Patients within the LEP group had an average baseline diastolic blood pressure of 85.09 mmHg
and a final diastolic blood pressure of 85.55 mmHg. An average increase of 0.45 mmHg in LEP
patient’s diastolic blood pressure was seen. Patients within the EP arm had average baseline
diastolic blood pressure of 86.23 mmHg and final systolic blood pressure of 84.72 mmHg. Unlike
the LEP group, the patients within the EP arm saw an average drop of -1.51 mmHg in their diastolic
blood pressure, p=0.484.
This difference in change in systolic and diastolic blood pressure translated to additional patients’
abilities within each arm to reach their blood pressure goal. At baseline, five patients (45.5%)
within the LEP arm and sixteen patients (34.0%) within the EP arm were at their blood pressure
goal. An additional patient (9.1%) within the LEP arm and twelve patients (25.5%) within the EP
reached their blood pressure goal of 140/90 mmHg by their final visit, p=0.238. At their final study
visit a total of six patients (54.5%) within the LEP arm and twenty-eight patients (59.6%) within
the EP arm were at their blood pressure goal.
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Blood Pressure and HbA1c Outcomes (Chart 3)
Blood Pressure
Baseline Systolic
Blood Pressure
Final Systolic Blood
Pressure
Change in Systolic
Blood Pressure
Baseline Diastolic
Blood Pressure
Final Diastolic Blood
Pressure
Change in Diastolic
Blood Pressure
Baseline Patients at
Blood Pressure Goal
Final Patients at
Blood Pressure Goal
Change in Number of
Patients at Goal

141.55 mmHg

143.23 mmHg

139.55 mmHg

138.62 mmHg

-2 mmHg

-4.62 mmHg

85.09 mmHg

86.23 mmHg

85.55 mmHg

84.72 mmHg

0.45 mmHg

-1.51 mmHg

5 (45.5%)

16 (34.0%)

6 (54.5%)

28 (59.6%)

1 (9.1%)

12 (25.5%)

8.45%
8.22%
-0.23%
6 (54.5%)

9.26%
8.97%
-0.29%
9 (19.1%)

6 (54.5%)

10 (21.3%)

0 (0%)

1 (2.1%)

0.470

0.484

0.238

HbA1c Outcomes
Baseline HbA1c
Final HbA1c
Change in HbA1c
Baseline Patients at
HbA1c Goal
Final Patients at
HbA1c Goal
Change in Number of
Patients at HbA1c
Goal

0.792

0.624

Patients within the LEP group had an average HbA1c of 8.45% and a final HbA1c of 8.22%. An
average change of -0.23% in LEP patient’s HbA1c was seen. Patients within the EP arm had an
average HbA1c of 9.26% and final HbA1c of 8.97%. A similar drop, -0.29%, was seen in the EP
group.
At baseline, six patients (54.5%) within the LEP arm and nine patients (19.1%) within the EP
arm were at their HbA1c goal. An additional patient (2.1%) within the EP reached their HbA1c
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goal of 9% by their final visit, p=0.624. At their final study visit a total of six patients (54.5%)
within the LEP arm and ten patients (21.3%) within the EP arm were at their HbA1c goal.
Discussion
This article details a small, unpowered, prospective study looking at the difference in volume and
categorization of drug therapy problems as well as the subsequent changes in patient adherence,
blood pressure, and HbA1c between patients who speak English or have limited English
proficiency. As was expected with the unpowered nature of this substudy of a larger project, a
statistically significant difference was identified for none of the primary and few of the secondary
outcomes. For the remainder of this section, how the results suggest further directions for research
in this area will be discussed.
Both arms of the study were predominantly female and had a similar overall age. Based on the
inclusion criteria of the study requiring patients to speak either Spanish or English, the less diverse
racial and ethnic breakdown of the LEP arm is understandable. Overall, patients within the English
proficiency arm had a higher rate of tobacco and alcohol use than those within the limited English
proficiency arm. The difference in alcohol use was statistically significant between arms. This
difference may be one factor that explains the higher baseline systolic and diastolic blood pressure
values in the EP arm.17 Though patients could be counseled on their alcohol and tobacco use as
part of the MTM appointments, it was not documented if any change in a patient’s alcohol or
tobacco use was made during the course of their visits.
Upon analysis of the patient’s comorbidities, patients within the LEP group had a higher rate of
five of the top six most common comorbidities. A statistically significant higher rate of diabetes
and hyperlipidemia was seen in the LEP population as well as a trend towards a higher rate of
asthma. Though patients within the EP arm had a slightly higher rate of ulcers than those within
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the LEP arm, on average, they had approximately two fewer comorbidities. The difference in the
number of comorbidities contributes to the difference in the total number of medications patients
taken within the two study arms. This belief is strengthened by the similar number of medications
per comorbidity seen in the two groups.
One factor, however, that has not been accounted for within the analysis of drug therapy problem
volume and categorization in this study is the higher number of overall medication use in the LEP
population. On average, the LEP population used 2.7 more medications per patient, a statistically
significant 40% increase from the EP arm. Results from the primary outcome of this study show
nearly identical numbers of drug therapy problems identified per patient, though the distribution
differed between the arms. Future studies may want to study this outcome in a population with a
similar number of medications used in both arms. The difference in the number of DTPs may
falsely appear to be similar on analysis within this study due to this confounder.
A small 2010 study also conducted in Connecticut analyzed the rate and types of medication
discrepancies and DTPs identified in Medicaid patients. The patients included in this study had an
average of 9.5 medical conditions and 15.7 prescription and non-prescription medications per
patient. Pharmacists identified an average of 10.4 DTPs per patient, over a five-fold increase from
the number of DTPs identified per patient in this author's analysis. It's important to note that
patients within the 2010 study had over two-fold the number of medications than the patients
within this study.18 However, the average number of DTPs identified in this study closely
resembles the average of 2.04 found in the Minnesota study published in 2005 that also compared
the LEP and EP populations.4
Upon analysis of drug therapy problem categorization, similarities were seen between the two
studies, supporting this study's drug therapy problem categorization results. Similar rates of DTPs
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were noted in Needs Additional Drug Therapy (21.7% vs 22.7%), Adverse Drug Reaction (17.4%
vs 15.7%), Needs Different Drug Product (8.7% vs 6.8%), Unnecessary Drug Therapy (4.3% vs
7.4%), and Dosage Too High (2.6% vs 4.9%). A higher rate of problems categorized as NonAdherence (36.5% vs. 26.2%) and a lower rate of problems categorized as Dosage Too Low (8.7%
vs. 16.3%) was seen in this author's analysis compared to the 2010 study.18
The results of this study suggest that there may be a higher rate of patients who have Unnecessary
Drug Therapy with limited English proficiency, which may account for some of the additional
medications seen in the LEP arm. This study also suggested that a larger proportion of patients
may have drug therapy problems categorized as Adverse Drug Reaction and Needs a Different
Drug Product in the EP arm, and a larger proportion of patients may have drug therapy problems
categorized as non-adherence in the limited English proficiency arm. In the 2005 study, there was
also a higher rate of DTPs categorized as non-adherence in the LEP population compared to
patients who spoke English as their primary language.4 Even with the provision of a bilingual
pharmacy technician to provide translation services, it appears that drug DTPs that require the
patient to communicate the problem to the healthcare provider, i.e., having an adverse reaction,
requiring another drug product, are still less likely to be identified in patients with limited English
proficiency. If these problems are not communicated, these problems may be inadvertently coded
as non-adherence in the LEP population, accounting for the higher rate seen in that arm. It is
possible that a smaller percentage of patients within the LEP arm were experiencing these
problems. However, this possibility is less likely due to the higher number of medications utilized
within the LEP arm. These results suggest that although adequate language services were provided
to patients, additional social determinants that pharmacists and other healthcare providers have not
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yet accounted for in their care of patients with limited English proficiency may be impacting the
appropriateness of, efficacy of, safety of, and adherence to drug therapy.
The difference in drug therapy problem categorization was not universal between all categories.
The rate of identification of Needs Additional Drug Therapy and Dosage Too Low were similar
between the two arms. To contrast the problems previously discussed, identification of these
problems would not require communication with the patient. Rather, pharmacists are able to
categorize these problems based off of their clinical knowledge and the patients’ comorbidities.
Patients within the EP arm had a lower baseline MMAS value, indicating worse baseline
adherence.16 Itis important to note, that this result conflicts with the higher rate of non-adherence
DTPs identified in the LEP population, which strengthens the theory that problems may be
incorrectly identified as non-adherence in this population. Because communication between health
care provider and LEP patients may be challenging and time-consuming, categorizing patients as
non-adherent may prevent the ability to identify the true cause of non-adherence. This may
inadvertently attribute the DTP to a patient cause, rather than a health-system cause. The accuracy
of identifying the appropriate DTP is critical to the eventual resolution of the DTP, and therefore
may affect health outcomes.
Though a similar numerical improvement in the MMAS value was seen within both arms, a
statistically significant difference was noted in how patients changed among the adherence
categories throughout the course of their visits. Though one patient in both arms fell into a lower
adherence category, zero patients within the LEP arm and six patients within the EP moved into a
higher adherence category throughout the course of their visits. Though a higher proportion of
patients within the LEP arm were categorized as having high adherence and had a higher average
MMAS value, the lack of upward movement between categories is noteworthy. This may be an
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indicator that additional strategies to improve adherence rates should be implemented for LEP
patients that are truly non-adherent in order to see the same clinically meaningful outcomes that
were observed in the EP population.
Patients within the EP had double the decrease in their systolic pressure compared to patients
within the LEP arm. Patients within the LEP had a slight increase in their diastolic pressure, while
patients within the EP group had an average 1.51 mmHg decrease in diastolic pressure. Though
these difference in values may not be statistically significant, the disparity should be noted for
future research with larger populations.
This disparity becomes more concerning when looking at individual patient’s ability to reach their
blood pressure goal. Though a higher proportion of patients within the LEP arm had reached their
blood pressure goal at baseline, only one additional patient was able to reach the goal in this arm.
However, over a quarter of patients within the EP arm reached their blood pressure goal during
the course of their MTM visits, leading to a higher proportion of patients at goal at their final visit
in the EP arm.
As described above, this difference in the outcomes related to blood pressure may be due to the
increased rates of smoking and alcohol use in patients with English proficiency and subsequent
counseling they received as part of this study. However, this disparity may be further evidence that
even when language services are provided to LEP patients; there may be additional socioeconomic
or cultural barriers in place that prevent them from reaching the same health outcomes as English
proficient patients given the same resources.
Patients within the EP arm had a higher baseline HbA1c. Though no additional patients within the
LEP population reached their A1c goal during the study period, this is likely due to the large
percentage of patients that were already at goal at baseline. In contrast to outcomes related to blood
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pressure, it is reassuring that a similar drop in HbA1c was seen in both study arms, and their final
visit a greater proportion of patients within the LEP arm were at goal. Unlike the outcomes related
adherence and blood pressure, it does not appear that a patient’s lack of English proficiency
provided a significant barrier to their ability to lower their HbA1c or reach the HbA1c goal. It is
important to note, however, that the high proportion of LEP patients already at their HbA1c goal
may have prevented this small analysis from discerning a difference in these outcomes.
This study was designed as a small, unpowered, prospective trial. Further investigation of these
outcomes in a powered study is required to either support or refute the results of this study in terms
of differences of drug therapy problems seen in both populations and outcomes related to
adherence and blood pressure and diabetes control.
There were a number of limitations to this study, many of which have been previously discussed.
The first and largest limitation of the study is its small size and unpowered nature. Though our
results can suggest potential differences in these populations, further studies should be conducted
before the results of this study can be interpreted. On a similar note, the results of this study stem
from a single site limiting the external validity of the results. Due to the single-site and small nature
of this study, interventionist bias in patient selection and visit conduction cannot be excluded. As
previously stated, the difference in the number of medications taken by patients within the LEP
population and the EP population likely confounded this study’s analysis in the difference in the
number of drug therapy problems identified. The last limitation of this study concerns the
collection of patient medication data. The number of medications a patient is taking was calculated
through the number of medications recently filled at Arrow Pharmacy in Hartford, CT and any
over-the-counter or herbal medications that may be listed on the patient’s visit sheet. This method
of data collection fails to account for any over-the-counter or herbal medication not reported by
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the patient or documented by the pharmacist, any medications that are filled at another site, or
medications taken periodically by the patient.
In summation, the results of this small prospective study suggest that there may be a difference in
how drug therapy problems are categorized and the subsequent control of chronic health conditions
in patients with limited English proficiency even when language services are provided.
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